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1Division of Hematology, University of Udine, Italy, 2Division of Hematology, UCSC, Rome, Italy and 3SEIFEM Group, Italy
Summary This multicentre observational study evaluated the feasibility, efficacy and toxicity of
antifungal combination therapy (combo) as treatment of proven or probable invasive
fungal diseases (IFDs) in patients with haematological malignancies. Between Janu-
ary 2005 and January 2010, 84 cases of IFDs (39 proven and 45 probable) treated
with combo were collected in 20 Hematological Italian Centres, in patients who
underwent chemotherapy or allogeneic haematopoietic stem cell transplantation for
haematological diseases. Median age of patients was 34 years (range 1–73) and
37% had less than 18 years. Acute leukaemia was the most common underlying
haematological disease (68/84; 81%). The phase of treatment was as follows: first
induction in 21/84 (25%), consolidation phase in 18/84 (21%) and reinduction/sal-
vage in 45/84 (54%). The main site of infection was lung with or without other
sites. The principal fungal pathogens were as follows: Aspergillus sp. 68 cases (81%),
Candida sp. six cases (8%), Zygomycetes four cases (5%) and Fusarium sp. four cases
(5%). The most used combo was caspofungin+voriconazole 35/84 (42%), caspofun-
gin + liposomal amphotericin B (L-AmB) 20/84 (24%) and L-AmB+voriconazole
15/84 (18%). The median duration of combo was 19 days (range 3–180). The over-
all response rate (ORR) was 73% (61/84 responders) without significant differences
between the combo regimens. The most important factor that significantly influenced
the response was granulocyte (PMN) recovery (P 0.009). Only one patient discontin-
ued therapy (voriconazole-related neurotoxicity) and 22% experienced mild and
reversible adverse events (hypokalaemia, ALT/AST increase and creatinine increase).
The IFDs-attributable mortality was 17%. This study indicates that combo was both
well tolerated and effective in haematological patients. The most used combo regi-
mens were caspofungin + voriconazole (ORR 80%) and caspofungin + L-AmB (ORR
70%). The ORR was 73% and the mortality IFD related was 17%. PMN recovery
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during combo predicts a favourable outcome. Clinical Trials Registration:
NCT00906633.
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Introduction
Recent data from haematological series suggest that
mortality attributable to invasive fungal infections
(IFDs) has decreased, probably due to the application
of a correct and timely diagnostic evaluation and to
the availability of newer, well tolerated and more effi-
cacious drugs (echinocandins, extended spectrum
triazoles, lipid formulations of Amphotericin B).1–4
However, the efficacy of current antifungal therapies is
still suboptimal, particularly in some categories of
patients (allogenic HSCT recipients) or in some rare
fungal infections (zygomycosis, fusariosis).2,3 The
expansion of the antifungal armamentarium led to the
opportunity to revise the traditional approaches to
treat IFDs and to the chance to further improve the
outcome.
Combination antifungal therapy (combo) is not a
new concept, as its role has been well established for
various infectious diseases, such as cryptococcal men-
ingitis.5,6 Unfortunately, whether combo may affect
the outcome of IFDs is still controversial, since only
limited data are available. This is even more unclear
for the issue of rare non-Aspergillus moulds. A large
number of studies performed in vitro or in animal
models have examined the effects of combo suggesting
potential benefits for difficult-to-treat mycosis.7–13
Unfortunately, results of preclinical studies cannot be
translated into clinical decisions and many unan-
swered questions do persist. Efficacy and safety still
need to be proved, particularly in the setting of a pro-
spective clinical trial.
The aim of this multicentre observational study was
to collect data on the use of this off-label treatment for
proven and probable IFDs among Italian Hematologi-
cal Centres and to assess the feasibility, toxicity and
efficacy of antifungal combo strategy in patients with
haematological malignancies.
Patients and methods
Patients with any type and stage of haematological
malignancy and patients undergoing autologous or
allogeneic HSCT were considered eligible for this
survey. All participating centres had received a spe-
cific Case Report Form to retrospectively register all
cases treated with combo. Patient data were queried
for haematological underling disease, medical history,
predisposing factors to IFDs, IFD sites and aetiology,
IFD-related therapy and outcome. The presence of
neutropenia was assessed at baseline and at the end
of combo for all cases. The Platelia Aspergillus
enzyme-linked immunoassay (Bio-Rad, Redmont,
WA) was used to detect galactomannan and index
of 0,5 or greater in two consecutive samples was
considered as positive.4,14 All reported cases were
reviewed by two independent physicians (AC and
LP) and only those identified as proven or probable
IFDs (according to EORTC criteria) were included in
the survey.14
Efficacy of combo was based on the investigator
assessment at the end of treatment (considering clini-
cal, radiographic and microbiological response). In
line with current standard definitions, both complete
(CR) and partial responses (PR) were considered as
success; all other responses were classified as fail-
ure.15 In particular, patients were considered refrac-
tory to the treatment if clinical and radiological signs
indicated a progressive infection after at least 7 days
of antifungal combo therapy with adequate drug
doses. Toxicity was evaluated and graded in accor-
dance with WHO criteria.
Overall mortality was defined as any death within
12 weeks from the diagnosis of proven or probable
IFD. Mortality was considered attributable to the IFD
(IFD-attributable mortality) when patients died within
12 weeks from the onset of a fever with microbiologi-
cal, histological, or clinical evidence of an active IFD
and if other potential causes of death could be
excluded by the responsible physician.
Statistical analysis
Univariate analysis was performed using the chi-
squared test with the following independent variables:
age (cut-off 50 years), paediatric or adult patient
(cut-off 18 years), certainty of diagnosis (proven vs.
probable), status of haematological malignancies
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(active or in remission), days of therapy (using cut-
off 14 days), neutrophil count (PMN) at the end of
therapy (cut-off 500/mmc), type of combo treatment
(sequential vs. ex novo). Multivariate analysis was
performed using a logistic regression model. Adjusted
HRs and 95%-CIs were calculated. Statistical signifi-
cance was set at P-value < 0.05. Endpoint for uni-
variate and multivariate analysis was response to
combo antifungal treatment (partial and complete
responses). Survival curves were generated by the
Kaplan–Meier method. Overall survival (OS) was cal-
culated from the data of IFD diagnosis to death or to
the last date of follow-up. The impact of clinical vari-
ables on survival was evaluated using the Cox hazard
regression. The statistical analysis was performed
using MedCalc version 12.5.0.0 (MedCalc statistical
Software bvba, Belgium).
Results
From January 2005 to January 2010, 84 cases of
combo were collected among the 20 participating Ital-
ian centres. They were 38 females and 46 males with
a median age of 34 years (range 1–73). Thirty-one
patients were younger than 18 years (paediatric
cases), but only 3/31 were less than 3 years old. All
cases had haematological disease, as reported in
Table 1, and 35% (29/84) of them had undergone
HSCT.
Acute leukaemia was the most common underlying
haematological disease (68/84; 81%).
The majority of patients had refractory or relapsing
disease (45/84, 54%), whereas the remaining were at
the onset of their disease (21/84, 25%) or in remission
(18/84, 21%).
Causative agents and infection sites
IFDs were classified as proven in 39/84 cases (46%)
and probable in 45/84 cases (54%). The site of IFD
was lung in 56 of 84 patients (67%) whereas 25/84
(30%) of cases had disseminated infections with two
or more sites involved.
Aspergillus species was identified as causative agent in
the majority of cases (68/84, 81%) (Table 1). In detail,
the causative agents in proven IFD cases were as fol-
lows: Aspergillus fumigatus (6), Aspergillus flavus (5),
Aspergillus niger (2), Aspergillus terreus (1), Aspergillus
sp. (9), Fusarium sp. (4), Mucor sp. (2), Rhizopus (2),
Candida not albicans (6), Blastoschizomyces (1) and Peac-
illomyces (1).
Previous therapy
A total of 57/84 (68%) of patients had received previ-
ous antifungal prophylaxis with fluconazole (31/57),
itraconazole (20/57), posaconazole (3/57) or L-AmB
(3/57). Hence, 67/84 (80%) had received a previous
antifungal monotherapy (empiric 39/67, preemptive
22/67 or target 6/67), with a median duration of
9 days (range 3–46). Prior antifungal therapies
included amphothericin B lipid formulations (45/84,
54%), caspofungin (10/84, 12%), voriconazole (9/84,
11%), posaconazole or itraconazole (3/84, 4%). In
addition, 8/84 (10%) patients had previously received
more than one line of antifungal monotherapy.
Table 1 Patient and IFD characteristics.
Total cases 84
Age (years) Duration of combo therapy
Mean  SD 35  21 Mean  SD 31  33
Median (range) 34 (1–73) Median (range) 19 (3–180)
IFD diagnosis (EORTC/MSG)
Adult patients 53/84 Proven 39/84 (46%)
Paediatric patients 31/84 Probable 45/84 (54%)
Underlying haematological disease Fungal pathogens
Acute leukaemia 68/84 Aspergillus spp. 68/84
Lymphoma/myeloma 5/84 Zygomycetes 4/84
MDS/SAA 6/84 Fusarium spp. 4/84
Chronic leukaemia 5/84 Candida spp. 6/84
Other* 2/84
Status of underling disease Sites of IFD
Onset 21/84 Pulmonary 56/84
Relapse/refractory 45/84 Paranasal sinuses only 3/84
Complete remission 18/84 Disseminated (two sites or more) 25/84
Previous stem cell transplant 29/84 (35%) Surgery 14/84
*1 Blastoschizomyces; 1 Peacillomyces; SAA, severe aplastic anaemia; MDS, myelodysplastic syndromes.
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The neutrophil count (PMN) at the start of combo was
below 1000/mmc in 75% of cases and 56/84 (67%)
patients had PMN less than 500/mmc. Only 21/84
(25%) of patients had more than 1000 PMN/mmc.
Type of combo
Combo antifungal therapy was started de novo (with
two new antifungal drugs) in 45/84 patients (54%)
whereas in 39/84 cases (46%) it was a sequential
therapy, adding a new antifungal agent to the prior
antifungal monotherapy. The most frequently used
combo was as follows: caspofungin + voriconazole
(35/84, 42%), caspofungin + liposomal amphotericin
B (L-AmB) (20/84, 24%) and L-AmB + voriconazole
(15/84, 18%) (Table 2). The median duration of
combo was 19 days (range 3–180).
Response to treatment and prognostic factors
The overall response rate (ORR) was 73% (61/84
responders) with 29 (35%) of CR and 32 (38%) of PR,
without significant differences between the combo reg-
imens as reported in Table 2.
If we consider the response to combo according to
the different causative agents we had: 71% (48/68) of
ORR in Aspergillosis, 50% (2/4) of ORR in Zygomyco-
sis, 100% (6/6) in Candidiasis and 75% (3/4) in
Fusariosis.
No differences in terms of ORR were recorded between
paediatric and adult cases (81% vs. 71% respectively;
P 0.4). However, paediatric cases (31) compared to
adult patients (53) had these significant differences:
more frequent use of caspofungin + voriconazole com-
bination (19/31 vs. 15/53; P 0.006), longer duration of
combo therapy (40 vs. 18 days; P 0.005) and more
frequent use of surgery (9/31 vs. 5/53, P 0.004).
In 14/84 cases of IFDs (nine paediatric and five
adult patients) the combo was associated with a surgi-
cal approach including: lung lobectomy (9 cases), liver
lobectomy (2 cases), tonsillectomy (1 case), vitrectomy
(1 case) and excision of mycotic brain abscess (1 case).
The ORR of combo plus surgery in these cases was
79% (11/14).
In univariate analysis, the only factor that signifi-
cantly influenced the response of combo was PMN
recovery (PMN greater than 500/mmc) during combo
(P-value 0.001) and the type of IFD (proven vs. proba-
ble IFDs, P-value 0.02). Other factors such as patient’s
age (greater or less than 50 years, paediatric cases vs.
adults), status of underlying disease, previous antifun-
gal prophylaxis, strategies for use of antifungal drugs
(sequential vs. de novo combo), and duration of combo,
did not affect the outcome (Table 3). At multivariate
analysis, only PMN recovery during combo remained
significant (P-value 0.009).
Toxicity of combo
Overall, combo was well tolerated. No serious side
effects were observed. Only one patient discontinued
therapy (voriconazole-related neurotoxicity) and 22%
experienced mild (grades I–II WHO) and reversible
adverse events (hypokalaemia, liver toxicity and tran-
sient creatinine increase) (Table 4).
Follow-up
After combo, 74% (45/61) of responsive patients
received a maintenance therapy with oral voriconazole
(34) or posaconazole (11) for a median of 62 days
(range 14–380).
After a median follow-up of 4 months (range 1–48),
48/84 (57%) of the patients included in this study
have died, mainly due to the refractory or progressive
underlying haematological disease. In 14 cases, the
IFD was the primary cause of death, with an IFDs-
attributable mortality rate of 17% (14/84 cases).
At 12- and 24-week probability of survival (OS) of
these patients was 62% and 52%, respectively
Table 2 Responses (overall response rate, ORR; complete response, CR; partial response, PR) to combo therapy in proven and probable
IFD.
Combo therapy and responses Total cases ORR CR PR NR
Caspofungin + Voriconazole 35 (42%) 28 (80%) 14 14 7
L-AMB + Caspofungin 20 (24%) 14 (70%) 10 4 6
L-AMB + Voriconazole 15 (18%) 11 (73%) 2 9 4
L-AMB + Caspo + Vorico 5 (6%) 2 (40%) 1 1 3
L-AMB + Posaconazole 4 (5%) 3 (75%) 1 2 1
Abelcet + Caspo or Vorico 2 (2.5%) 1 (50%) 0 1 1
Caspofungin + Posaconazole 3 (4%) 2 (67%) 1 1 1
Total 84 61 (73%) 29 (35%) 32 (38%) 23 (27%)
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(Fig. 1A). The responsive patients to the combo had
better OS than non-responder cases and the patients
who recovered PMN (>500/mmc) during combo had
significantly better survival than neutropenic
(PMN < 500/mmc) cases (75% vs. 34% at 12 week, P
0.005) (Fig. 1B).
Discussion
The combo antifungal therapy is still an open issue in
haematology because the potential advantages com-
pared to monotherapy are not yet demonstrated.16–20
Well-designed and randomized trials are required to
define the role of this strategy in haematological
patients. However, performing a combination trial in
the clinical setting of proven/probable IFDs would be
expensive and quite challenging.16–20 In fact, more
than 500 cases are required to perform a randomized
trial with an adequate power in this context.16–20
In vitro and experimental animal models produced
very promising results in terms of efficacy and tolera-
bility of this therapeutic approach.7–13 However, as we
do not have any large prospective and randomized
clinical trial with an adequate statistical power, combo
in IFDs has now a low level of evidence and recom-
mendation in all current international guidelines.21–24
In this study, we report the results of a real-life
experience in haematological patients.
Despite the limits of our study design (observational,
not randomized) we think it may be of help in display-
ing the current role of combo in daily clinical practice
and in analysing its tolerability and feasibility in hae-
matological patients with proven/probable IFDs. Over-
all, combo antifungal therapy has been rarely used in
the 20 participating centres over 2005–2010 (less
than one case/year/centre), mostly in patients with
acute leukaemia or after allogeneic HSCT. The most
common combinations were those including caspofun-
gin (included in 76% of combinations), voriconazole
(in 67% of combinations) or L-AmB (in 52% of combi-
nations). The ORR was 73% (with 35% CR and 38%
PR) and the only factor significantly associated with
response to combo, in multivariate analysis, was the
PMN recovery during therapy.
In our experience, combo resulted to be well toler-
ated, both in children and in adult patients, and only
one of them had to withdraw of treatment (1.2%) for
voriconazole-related and reversible neurotoxicity. It is
worth noticing that the IFDs-related mortality in this
study was low (17%, 14/84 cases) and, as expected,
that patients responsive to the combo had a signifi-
cantly better survival than non-responsive cases.
The literature data on combo in haematology focus
mainly on invasive aspergillosis (IA) and mucormyco-
sis and seem to confirm the utility of this therapeutic
approach. A summary of recent published clinical
studies evaluating combination therapy for IA in hae-
matological patients is reported in Table 5.25–35
In the context of IA, only two prospective studies on
antifungal combo have been published.25,26 In the first
one, 53 patients with prevalence of pulmonary IA
(81%) were treated with caspofungin in combination
Table 3 Factors affecting response to combo antifungal therapy.
Response to combo therapy-univariate analysis Response to combo therapy-multivariate analysis
Variable HR 95% CI P Value Variable HR 95% CI P Value
Age ≥ 50 vs. <50 0.88 0.33–2.35 0.79
Adult vs. paediatric patients 1.22 0.46–3.30 0.69
Proven vs. probable IFD 3.34 1.16–9.62 0.02 Proven vs. probable IFD 2.10 0.65–6.80 0.22
Active haematological
disease vs. remission
0.28 1.06–1.31 0.07 Active haematological disease vs.
remission
0.76 0.13–0.39 0.76
Days of therapy >14 vs. ≤14 1.02 0.99–1.04 0.1 Days of therapy >14 vs. ≤14 1.30 0.43–3.95 0.64
PMN at stop >500/mmc vs.
≤500/mmc
0.19 0.07–0.53 0.001 PMN at stop >500/mmc vs.
≤500/mmc
0.21 0.07–0.68 0.009
Combo ex novo vs. Combo
addition
1.94 0.72–5.24 0.19
HR, hazard ratio; 95% CI, 95% confidential interval.
Table 4 Combo therapy and side effects.
Side effects
Paediatric
patients
Adults
patients All cases
Hypokalaemia (I–II WHO) 4/31 4/53 8/84 (10%)
Liver toxicity (I–II WHO) 2/31 2/53 4/84 (5%)
Renal toxicity (I–II WHO) 1/31 2/53 3/84 (4%)
Neurologic toxicity 0/31 2/53 2/84 (3%)
Stop due to toxicity 0/31 1/53 1/84 (1.2%)
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with other antifungals; the most common underlying
disease was acute leukaemia (53%) and most patients
(87%) were refractory to prior antifungal therapy. The
use of combo resulted in an ORR of 55% (29/53).
Fifty-seven per cent of patients with neutropenia and
54% who had received an allogeneic HSCT responded
favourably with proportion of survivors being 55% by
day 84. Combo was well tolerated. Two (4%) serious
drug-related adverse events were reported, both attrib-
uted to voriconazole. None of the patients discontinued
caspofungin due to toxicity. This analysis showed that
caspofungin in combination with a triazole or polyene
was an effective alternative to salvage monotherapy
for patients with IA.25
In the second prospective study (Combistrat pilot
trial) only 30 patients with haematological
malignancies were analysed (15 in each arm). The
median duration of treatment was 18 days for the
combo group (caspofungin plus standard dose of L-
AmB) and 17 days for the high-dose monotherapy
group (L-AmB 10 mg Kg1 per day). At the end of
treatment, the ORR in the combo arm was signifi-
cantly superior (67%) compared to monotherapy
(27%; P 0.028). Survival rates at 12 weeks were
100% and 80% respectively. Infusion-related reactions
occurred in three patients in the high-dose monothera-
py arm. A twofold increase in serum creatinine
occurred in four of 17 patients (23%) who received
high-dose monotherapy and one of 15 patients (7%)
who received combo.26
As for retrospective studies in IA, Kontoyiannis et al.
[27] analysed 48 cases of documented (23) or possible
(25) progressive IA, treated with caspofungin plus L-
AmB (65%) as salvage therapy, following 7 or more
days of a previous L-AmB monotherapy. The ORR was
42% and no significant toxic effects were seen. In the
retrospective analysis by Aliff et al. [28], 30 haemato-
logical patients were treated with caspofungin plus L-
AmB. The median duration of combo was 24 days and
the ORR was 60%. In a small, single-centre study, Marr
et al. [29] evaluated the outcome of 47 patients with
IA who experienced failure of first-line therapy with
AmB formulations and received either voriconazole
(31) or a combination of voriconazole and caspofungin
(16) for salvage therapy. The combo of voriconazole
plus caspofungin was associated with an improved 3-
month survival compared to voriconazole alone.
Another very recent retrospective analysis by Rojas
et al. [30] reported the outcome of 61 haematological
patients treated with different combinations in Spanish
Hematologic Centers (L-AmB + caspo, 20; L-AmB +
triazole, 20; voriconazole+echinocandin, 21). Combo
was well tolerated and 38 (62%) patients achieved a
response (with 35 CR), regardless of the combo type.
We have also to underline that Marr et al. presented
at ECCMID 2012 the final results of the largest (459
patients) prospective, randomized 1:1, phase III trial
that compares efficacy and safety of voriconazole plus
anidulafungin or placebo in newly diagnosed IA. This
study was conducted at 93 sites from 2008 to 2011
and the primary endpoint was 6-week all-cause mor-
tality. Results demonstrated that in the modified
intent-to-treat population, 6-week mortality was
19.3% for the patients in voriconazole plus anidula-
fungin group and 27.5% for the patients in voriconaz-
ole plus placebo group (P 0.09). This study showed,
for the first time, that a combination of two antifun-
gals determines a reduction in early mortality.
(a)
(b)
Figure 1 (A) Overall Survival (in weeks) of the whole population
(84 cases). (B) Overall Survival according to PMN recovery dur-
ing combo therapy.
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The evidences on clinical efficacy and tolerability of
the combo in Mucormycosis are even more limited,
given the rarity of this IFD. The SEIFEM and FUNGI-
SCOPE registries recently published the analysis of 32
cases of proven/probable invasive mucormycosis in
haematological patients treated with a combination of
L-AmB and posaconazole. Thirteen of them (41%) had
also received surgical excision of the infected tissue.
After a median follow-up of 3 months the ORR was
78% with 11 CR (34%), 7 PR (22%) and 5 stable dis-
eases (16%). These results suggest a beneficial role of
combo plus surgery in invasive mucormycosis.36
In summary, all these experiences, although difficult
to compare, suggest that combo is well tolerated and
it seems to be effective either as first or second line,
with an ORR greater than 50% in aspergillosis and
mucormycosis.25–37
However, the use of combo antifungal therapy may
be limited by some drawbacks, like the higher costs
when compared to single antifungal agents.
The emergence of resistant strains to antifungal
drugs is also strictly related to the issue of combo
because a resistant fungal pathogen should be sus-
pected in patients not responsive to first-line antifungal
monotherapy.38,39 This could justify, in selected unre-
sponsive patients the use of combo, especially when
in vitro tests of resistance are not available.
In conclusion, this multicentre observational study
on antifungal combo, as treatment of proven or proba-
ble IFDs in haematological patients, confirms the feasi-
bility and good tolerability of combo and supports
previous data on its efficacy.
The use of combo may be justified, in patients with
responsive haematological cancer and proven or prob-
able IFD, as antifungal bridge until PMN recovery
occurs. In clinical practice, the combo therapy can
also be used in combination with surgical approach
with the aim of eradicating an IFD that could delay
the entire therapeutic programme of underling haema-
tological disease.39 Clearly, a better characterization of
patients with a very high risk of IFDs is therefore
important for the selection of those who may be candi-
date to this kind of treatment as first-line approach.40
Finally, given the high costs of combo treatment, it
may also suggest to reserve combo to those patients
without refractory or progressive underlying haemato-
logical disease for whom we might expect a very good
life expectancy if IFD is cured.
In addition, well-controlled studies are still required to
adequately determine the most efficacious antifungal
combination regimens for specific fungal infections and to
evaluate the pharmaco-economic impact of this strategy.
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